Novel Targets
The central theme for session IV at the Myeloma2018 meeting was novel drug targets for MM targets. Nizar Bahlis, MD, and Enrique Ocio, MD, PhD, identify MCL-1 as a possible target in MM, indicating a potential niche for MCL-1 inhibitors. Leif Bergsagel, MD, Robert Orlowski, MD, PhD, and Keith Stewart, MBChB, explore further drug targets.
Presentations
Mayo Clinic, Phoenix, AZ
Leif Bergsagel, MD, PhD, from the Mayo Clinic, Phoenix, AZ, discusses targeting cctopic enhancer-driven oncogene dysregulation in multiple myeloma.
MD Anderson Cancer Center, Houston, TX
Robert Orlowski, MD, from the MD Anderson Cancer Center, Houston, TX, speaks about PROTACs targeting BRD4.
Mayo Clinic, Rochester, MN
Keith Stewart, MBChB, from the Mayo Clinic, Rochester, MN, discusses PIKfyve in myeloma.
University Hospital of Salamanca, Salamanca, Spain
Enrique Ocio, MD, PhD, from the University Hospital of Salamanca, Salamanca, talks about MCL-1 and BCL-2 inhibitors.
University of Calgary, Calgary, Canada
Nizar Bahlis, MD, from the University of Calgary, Calgary, Canada, discusses PROTAC-mediated degradation of MCL-1.
